ライフサイエンスコーパス: drug screen

1 erum alcohol levels and 350 [24.5%] by urine drug screens).

2 me, allowing applications such as genetic or drug screens.

3 or neurons to perform mechanistic studies or drug screens.

4 pecific small-molecule modulators in primary drug screens.

5 essed by self-reports and quantitative urine drug screens.

6 create new opportunities for high-throughput drug screens.

7 determined by serum alcohol levels and urine drug screens.

8 o use EHM for iPS-based disease modeling and drug screening.

9 ing of anti-cancer mechanism and anti-cancer drug screening.

10 iothreat detection, clinical diagnostics and drug screening.

11 ant clones were detected with clone-specific drug screening.

12 igation of the biology of CRC metastasis and drug screening.

13 mechanistic studies of tumor biology and for drug screening.

14 platform for vascular disease modelling and drug screening.

15 development, as well as disease modeling and drug screening.

16 ogical application, disease diagnostics, and drug screening.

17 to have application in cellular imaging and drug screening.

18 period of abstinence and 64% requiring urine drug screening.

19 for studying specific CPVT mutations and for drug screening.

20 f a hEPC endothelialized hMSC-based TEBV for drug screening.

21 polarization form a powerful combination for drug screening.

22 uloskeletal diseases in a dish and for rapid drug screening.

23 ove the disease relevance of assays used for drug screening.

24 thereby providing an excellent platform for drug screening.

25 le for fast high throughput anti-aggregation drug screening.

26 plications such as regenerative medicine and drug screening.

27 s, can be interrogated structurally to allow drug screening.

28 a, and in cell lines through high-throughput drug screening.

29 es, examination of human-specific genes, and drug screening.

30 w beta-cells for transplantation therapy and drug screening.

31 diagnosis, protein biomarkers screening and drug screening.

32 senting a bottleneck problem for large-scale drug screening.

33 s disciplines such as patient diagnostics or drug screening.

34 ritical when analyzing PTPs, for example, in drug screening.

35 in-vivo phenotypes, providing platforms for drug screening.

36 ET in preclinical therapeutic monitoring and drug screening.

37 eats of this technique and its potential for drug screening.

38 nomics, diagnostics, directed evolution, and drug screening.

39 the in vivo toxicity of nanoparticles or for drug screening.

40 for the study of disease mechanisms and for drug screening.

41 ools in regenerative medicine, bioassay, and drug screening.

42 may be used for testing carcinogenicity and drug screening.

43 egulation of oligodendrocyte development and drug screening.

44 al PCR, single-cell analysis, and cell-based drug screening.

45 regenerative medicine, disease modeling, and drug screening.

46 ary development and for disease modeling and drug screening.

47 showing great potential for high-throughput drug screening.

48 s, disease diagnostics, and chemotherapeutic drug screening.

49 nmental samples, and can also be applied for drug screening.

50 the migratory capability and anti-metastatic drug screening.

51 ential to enable more physiological in vitro drug screening.

52 n native HD tissue samples and for potential drug screening.

53 the CNS to allow pharmacological testing and drug screening.

54 stem cell research, tissue engineering, and drug screening.

55 study cancer cell migration and anti-cancer drug screening.

56 has been developed towards a high throughput drug screening.

57 lene) glycol diacrylate (PEGDA) hydrogel for drug screening.

58 e a good model for further investigation and drug screening.

59 es to perform rapid, large-scale genomic, or drug screening.

60 udies of neurotransmitter-enzyme binding and drugs screening.

61 evelop automated, quantitative approaches to drug screening against helminth diseases.

62 Drug screening against helminths has often been phenotyp

63 triatal pathologies, paving the way for easy drug screening against PD.

64 Previous drug screens aiming to identify disease-modifying compou

65 or organoids are amenable to high-throughput drug screens allowing detection of gene-drug association

66 -care diagnostics application and anticancer drug screen and discovery.

67 rafish lateral line system as a platform for drug screen and subsequent validation in the rat cochlea

68 of the NCI human tumor cell line anticancer drug screen and the NCI COMPARE algorithm, it appears th

69 hPSCs) offer many potential applications for drug screening and 'disease in a dish' assay capabilitie

70 sculogenic cell types for basic research and drug screening and can contribute to angiogenic regenera

71 promise in disease modelling, pharmaceutical drug screening and cell therapy for Huntington's disease

72 tial cell source for heart disease modeling, drug screening and cell-based therapeutic applications.

73 Cs) are used as platforms for disease study, drug screening and cell-based therapy.

74 ing an increasingly useful in vitro tool for drug screening and delivery to pathological tissues and

75 classifying cells based on their viability, drug screening and detecting populations of malignant ce

76 toward various forms of xenograft models for drug screening and development.

77 chanisms, and metabolic pathways, through to drug screening and discovery as well as medical imaging.

78 ticipate the widespread adoption of MPSs for drug screening and disease modeling.

79 used for various applications such as early drug screening and disease modeling.

80 PSCs) are essential to personalized in vitro drug screening and disease study.

81 ial cardiomyopathies as well as for in-vitro drug screening and drug discovery.

82 form will greatly facilitate high-throughput drug screening and electrophysiological characterization

83 without the use of solvents, can accelerate drug screening and enable continuous manufacturing, whil

84 LTP in AD, thus opening up a new avenue for drug screening and evaluation of strategies for alleviat

85 this powerful new set of tools for improved drug screening and for investigating early mechanisms dr

86 ngineered environments open new -avenues for drug screening and fundamental studies of wound healing,

87 ation of high-quality chemical libraries for drug screening and in applications such as drug repositi

88 Future applications such as drug screening and in point of care applications are the

89 in vivo models of C. difficile infection for drug screening and lead optimization.

90 y diverse human sensory neurons suitable for drug screening and mechanistic studies.

91 gs validate a unique BCSC culture system for drug screening and offer preclinical proof of concept fo

92 aterial for therapeutic intervention such as drug screening and potentially also for cell-based thera

93 ul platform in cases such as high-throughput drug screening and prolonged drug release.

94 nerative medicine, modeling of lung disease, drug screening and studies of human lung development.

95 nerative medicine, modeling of lung disease, drug screening and studies of human lung development.

96 iological models of human cancers for use in drug screening and studying cancer biology.

97 ial for investigating PPIs in the context of drug screening and target validation applications.

98 ranslational pain research, and enable rapid drug screening and testing of newly engineered opsins.

99 ion kinetics for many applications including drug screening and the investigation of the mechanisms o

100 ially be used for the treatment of diabetes, drug screening and the study of beta-cell biology.

101 tential applications, including personalized drug screening and therapeutic strategies for liver fail

102 cal environment for MSC in disease modeling, drug screening and tissue engineering.

103 genetic backgrounds would be beneficial for drug screening and to provide a source of cells to be us

104 cs screening-e.g., for clinical phenotyping, drug screening and toxicity testing.

105 ernatives to animal and clinical studies for drug screening and toxicology applications.

106 y emerging as a promising model organism for drug screening and translational neuroscience research.

107 as a tool for medium-throughput antimalarial drug screening and vaccine development.

108 We find, using a combination of large-scale drug screening and whole-exome sequencing, that our erlo

109 Cocaine use was quantified weekly by urine drug screens and participant report using the timeline f

110 avy drinking (measured by twice-weekly urine drug screens and self-report) and time to dropout from t

111 t, therefore, be amenable to industrial (eg, drug screening) and clinical (eg, cardiac repair) applic

112 Institute Human Tumor Cell Line Anti-Cancer Drug Screen, and the NCI COMPARE algorithm did not revea

113 nderstanding of cancer pathology, anticancer drug screening, and cancer treatment development.

114 otency, and allow in-vitro disease modeling, drug screening, and cell replacement therapy.

115 tial cell source for heart disease modeling, drug screening, and cell-based therapeutic applications.

116 ker discovery, molecular interaction assays, drug screening, and clinical diagnostics.

117 f applications such as inflammation studies, drug screening, and coculture interactions.

118 use as an efficient model for candidate NPC1 drug screening, and demonstrated similarities in hepatic

119 Tissue engineering, gene therapy, drug screening, and emerging regenerative medicine thera

120 llenge for applications in disease modeling, drug screening, and heart repair.

121 (iPSC) technology for the cellular therapy, drug screening, and in-vitro modeling of neurodegenerati

122 mplications in functional molecular studies, drug screening, and iPS cell-based platforms for disease

123 ould have broad utility in disease modeling, drug screening, and regenerative medicine.

124 using iPSC technology for disease modeling, drug screening, and the development of stem cell therape

125 such as cancer detection, probe development, drug screening, and therapy monitoring.

126 re unlikely to be found through conventional drug screening, and they include kinase inhibitors and d

127 parasites suitable for in vitro and in vivo drug screening, and we evaluated the basis of drug susce

128 patient-specific cells for disease modeling, drug screens, and cellular therapies.

129 l-based and protein function-based multiplex drug screens, and concurrently discovers therapeutic com

130 fmol, which would be a useful attribute for drug screening applications or testing of small quantiti

131 yte detection and is particularly suited for drug screening applications.

132 nsplantation, human antibody generation, and drug screening applications.

133 underscoring the potential of the system for drug screening applications.

134 s very attractive for tissue engineering and drug screening applications.

135 We used a phenotypic drug screening approach to identify ethoxyquin as a pote

136 des a powerful tool for disease modeling and drug screening approaches.

137 The basis of the next generation of drug-screening approaches is set to be in silico risk pr

138 High-throughput drug screens are powerful tools for determining kinase d

139 d by topoisomerase inhibitors in an oncology drug screening array and altered variant composition of

140 viously identified in a large-scale unbiased drug screen as promoting increased lifespan in worms.

141 ystem as an alpha-synuclein anti-aggregating drug screening assay a panel of 10 drugs was tested.

142 cal proteomics and an organotypic cell-based drug screening assay, we determine the functional role o

143 nal multi-assay algorithm and antiretroviral drug screening assay.

144 limit of 10 pg/ml, as well as demonstrated a drug screening assay.

145 atform provided a rapid ( approximately 1 h) drug screening assay.

146 Using a cell-based drug-screening assay, we identified Acriflavine (ACF), a

147 Fluorescent drug screening assays are essential for tyrosine kinase

148 New reliable and cost-effective antimalarial drug screening assays are urgently needed to identify dr

149 Drug screening assays identified a compound targeting th

150 es a potential natural substrate peptide for drug screening assays, and also reveals a potential func

151 enerative diseases and in proof-of-principle drug-screening assays.

152 l microarray imaging approach for anticancer drug screening at specific cancer protein-protein interf

153 of cardiac function, transgenic animals, and drug screens based on variable E1 stoichiometry do not r

154 lytes, immunoassays, gene expression assays, drug screening, bioimaging of live organisms, cancer stu

155 conduct patient-specific in vivo and ex vivo drug screens, but stromal contributions to treatment res

156 Using in silico drug screening by Connectivity Map followed by empirical

157 low exchange that are not easily amenable to drug screening by traditional NMR methods.

158 ate the power of lineage-specific cell-based drug screens by identifying a compound that promotes sur

159 sing a panel of AMD biomarkers and candidate drug screening, combined with transcriptome analysis, we

160 e canine osteosarcoma tumor cultures using a drug screen consisting of 60 targeted drugs.

161 Therefore, an OMI organoid drug screen could enable accurate testing of drug respon

162 Next generation drug screening could benefit greatly from in vivo studie

163 n addition, the use of pluripotent cells for drug screening could enable routine toxicity testing and

164 FGFR inhibitors was determined by analyzing drug screen data and conducting in vitro and in vivo exp

165 g the National Cancer Institute's anticancer drug screen data, we identified two compounds from the t

166 an algorithm that integrates high-throughput drug screening data, comprehensive kinase inhibition dat

167 blicly available, high-quality DNA, RNA, and drug screening data.

168 on data linked to high-quality DNA, RNA, and drug-screening data have not been available across a lar

169 cally available genomic, transcriptomic, and drug-screening data.

170 of organ-on-a-chip systems, high-throughput drug screening devices, and in regenerative medicine.

171 potential for future applications including drug screening, diagnostic applications and functional a

172 here has been limited progress in iPSC-based drug screening/discovery for liver diseases, and the low

173 ssues offer enormous potential as models for drug screening, disease modeling, and regenerative medic

174 recapitulate human responses are needed for drug screening, disease modeling, and, ultimately, kidne

175 During a high-content drug screening effort, we identified AS601245 as a poten

176 Drug screening efforts and subsequent structural and mec

177 ro studies of degenerative mechanisms or for drug screening efforts.

178 ience and neuroendocrine research as well as drug screening efforts.

179 Through a blind large-scale drug screening, five clinical drugs were identified to r

180 can, were recently identified in an unbiased drug screen for compounds that could reverse the silent

181 many potential applications in modeling and drug screening for airway diseases.

182 Drug screening for antimalarials uses heme biocrystalliz

183 We describe a new approach to proteome-wide drug screening for detection of on- and off-target bindi

184 tool for basic discovery and high-throughput drug screening for G-protein-coupled receptors and ion c

185 d to be useful for regenerative medicine and drug screening for liver diseases.

186 en developed and validated in the context of drug screening for schistosomiasis, one of the most impo

187 sing cellular tool to facilitate therapeutic drug screening for severe neurodevelopmental disorders.

188 in vivo tool for high-throughput therapeutic drug screening for the improvement of muscle phenotypes

189 To facilitate drug screening for this anaerobic protozoan, we develope

190 udies and should be incorporated early on in drug screens for broad-spectrum human soil-transmitted h

191 in future studies of disease mechanisms and drug screens for effective therapies in arrhythmogenic c

192 ration of sufficient cell numbers to perform drug screens, for the development of cell therapeutics o

193 entation, opioid treatment agreements, urine drug screens, frequent visits, and restricted quantities

194 enes which can be used for disease modeling, drug screening, gene correction and future in vivo appli

195 hnologies are urgently required for reliable drug screening given a worldwide epidemic of prescriptio

196 of this biosensor in future high throughput drug screening has the important potential to help ident

197 A mandatory drug screen implemented by many countries led to a disco

198 o accomplish this, we performed a non-biased drug screen in sapje, a zebrafish line with a recessive

199 viability of mouse ES cells, we performed a drug screen in search of specific inhibitors of the puri

200 ate this microfluidic device will facilitate drug screening in a relevant microenvironment thanks to

201 tform for genotype-phenotype correlation and drug screening in any human myelin disorder.

202 pigenetic biomarkers through high-throughput drug screening in approximately 1,000 molecularly annota

203 Our work lays the groundwork for label-free drug screening in pharmaceutical science and industry.

204 to antihypertensive treatment at 6 months by drug screening in urine/plasma samples from 85 patients.

205 ective tumours, we performed high-throughput drug screens in an isogenic NSCLC model of ERCC1 deficie

206 demonstrates the feasibility of undertaking drug screens in Parkinson's disease patients' tissue and

207 opens up the possibility of high-throughput drug screens in search of new classes of antidepressants

208 omimetic assays for interaction analysis and drug screening involving membrane components.

209 The applicability for drug screening is demonstrated by studying the effects o

210 Drug screening is facilitated by the incorporation of a

211 opment of a biomimetic 3D culture system for drug screening is necessary to fully understand the in v

212 need for a liver-on-a-chip tissue model for drug screening is particularly important in tissue engin

213 by a complete cell-based assay for efficient drug screening is performed showing a clear correlation

214 such as photodynamic therapy for accelerated drug screening, magnetically guided controlled drug deli

215 This convenient method for drug screening may facilitate the development of antivir

216 ons, we developed an efficient combinatorial drug screening method called the Feedback System Control

217 ues were analyzed initially by an anticancer drug-screening method based on a sulforhodamine B assay.

218 Here, by using in silico drug-screening methods, we discovered that Celastrol, a

219 inatorial printing, high-throughput parallel drug screening, modular disposable cartridge, and biocom

220 ghlight the PM as a high-fidelity target for drug screening of Kv channels.

221 However, high-throughput drug screening of P450s is limited by poor protein stabi

222 A combinatorial drug screen on multiple PIK3CA mutant cancers with decre

223 onstrate the applicability of our method for drug screening on dried blood spots showing excellent li

224 death and axonal degeneration, we performed drug screens on primary rodent neurons and identified th

225 s and should be valuable for high-throughput drug screening or biointeraction studies.

226 for relevant biosensing applications such as drug screening or cellular chips.

227 nique in scientific research, pharmaceutical drug screening or toxicity testing.

228 ions include gene discovery, high-throughput drug screens or systematic analysis of regulatory networ

229 , as a result, lead to new clinical care and drug screening paradigms, are discussed.

230 s demonstrate the efficacy of our model as a drug screening platform and a promising tool to investig

231 We validate our model as a drug-screening platform by identifying several compounds

232 omatography- mass spectrometry (LC-MS) based drug-screening platform we show that Metformin, a widely

233 HIV-1 diagnosis, as well as high-throughput drug screening platforms.

234 f human intestinal disease and in developing drug-screening platforms that more accurately represent

235 Proof of principle that the gene panel shows drug screening potential was obtained using a well-estab

236 Urine drug screens (primary outcome measure) and mood symptoms

237 l generic analytical applications, including drug screening, prion strain discrimination, biohazard s

238 as a rapid and reliable in vitro method for drug screening prior to in vivo testing.

239 A simple and cost-effective two-tier drug screening procedure comprises a 'dedicated' NIR spe

240 itro systems have significantly advanced the drug screening process as 3D tissue models can closely m

241 h can have a myriad array of applications in drug screening, programmable tissue engineering, drug de

242 stic studies of homologous recombination and drug screening programs.

243 ifferentiation into lineages for large-scale drug-screening programs and clinical use.

244 udy, we established a robust high-throughput drug screening protocol by using a recombinant RSV repor

245 bility of cells cultured in microsystems for drug screening purposes is usually tested with a variety

246 SM or CSPalpha aggregation as biomarkers for drug screening purposes.

247 inal cells for regenerative medicine and for drug-screening purposes, as well as an in vitro model of

248 mation from the descriptions of over 100,000 drug screening-related assays in rats and mice.

249 lular plasticity, possibly in the context of drug screening research and of future cell-replacement t

250 Furthermore, a synthetic lethal drug screen revealed that antagonists of the adenosine r

251 High-throughput drug screening revealed that bromodomain and extra-termi

252 y engraft in recipient mice, and preliminary drug screening reveals mutation-specific vulnerabilities

253 Targeted drug screening reveals that SCLC with high MYC expressio

254 nt in vitro models of muscle dystrophies and drug screening strategies, as well as providing a source

255 We developed a pooled shRNA-drug screen strategy to identify genes that, when inhibi

256 Using this model, we designed a drug screening strategy based on the pupal lethality phe

257 uired make zebrafish the model of choice for drug screening studies, when a valid disease model is av

258 potential in other clinical applications and drug-screening studies.

259 In the future, iMPCCs could prove useful for drug screening, studying molecular mechanisms underlying

260 biomolecules can yield useful platforms for drug screening, synthetic biology applications, diagnost

261 ough high-throughput genomics and innovative drug-screening systems.

262 d on MOCOS expression, and paves the way for drug screening targeting MOCOS and/or the purine metabol

263 re amenable for biomarker identification and drug-screening testing and led to the identification of

264 ype were more likely to have positive opioid drug screens than individuals in the combined CT and TT

265 dy limitation was weekly assessment of urine drug screens that decreased the ability to detect betwee

266 Applied to promyelination drug screening, the method uniquely enabled the identifi

267 ity of this organism for large-scale in vivo drug screening, thus providing unprecedented opportuniti

268 re bound to ligands in a 96-well-plate-based drug screen to assess the ability of promising small mol

269 s rapid disease modeling and high-throughput drug screening to alleviate astrocyte-derived toxicity.

270 cations ranging from medical diagnostics and drug screening to chemical and biological warfare detect

271 -germline neurofibroma model for preclinical drug screening to identify effective therapies.

272 , and develop platforms for, high-throughput drug screening to identify novel compounds to prevent an

273 provide a method for unbiased whole-organism drug screens to identify novel drugs and molecular pathw

274 is primary cell model can be used to perform drug screens, to study cytolytic T lymphocyte (CTL) resp

275 N transcription, thus making it an efficient drug screening tool that can be used for therapeutic int

276 seful for mechanical injury studies and as a drug screening tool, and it could serve as a foundation

277 llmarks of tissue-based bioassays, including drug screening, tumor dissemination, cell co-culture, an

278 Finally, a phenotypic drug screen using C. elegans identified podocarpic acid

279 We designed a combinatorial high throughput drug screen using well-characterized kinase inhibitor-fo

280 ted the feasibility of effective large-scale drug screening using an iPSC-based disease model and hig

281 Through a proof-of-principle drug screening using BICA, we found that danusertib, an

282 of lead compounds to patients, we conducted drug screening utilizing our established library of clin

283 he CFTR as a therapeutic target, a cell-free drug screen was established to identify modulators of NB

284 his system's biotechnological application in drug screening was successfully demonstrated by the N-ox

285 n of spheroid microarrays for spheroid-based drug screens was demonstrated by quantifying the dose-de

286 Using data from our large drug screen we predicted, and subsequently demonstrated,

287 Using these insights for a structure-based drug screen, we discovered novel 7-azaindole compounds t

288 Using a high throughput drug screen, we identified a number of compounds that co

289 Furthermore, in an unbiased drug screen, we identified the ability of sertraline (an

290 On the basis of a high-throughput drug screen, we provide preclinical proof of concept tha

291 Using an epigenetic pathway-targeted drug screen, we report that inhibitors of DNA methyltran

292 Using in vitro drug screening, we identified 211 amino-acid substitutio

293 Through a series of data analysis and drug screening, we identified two compounds (i.e., NSC-3

294 of the efficacy for potential anti-influenza drug screens, we have also demonstrated that the anti-in

295 Results of thrice-weekly urine drug screens were analyzed using a generalized linear mi

296 al ligand-binding approach for antipsychotic drug screening where competitive binding of a novel APD

297 control livers to design an "educated guess" drug screen, which led to the identification of new, del

298 ve the efficacy and accuracy of OCT in vitro drug screening will greatly contribute to the field of c

299 opens a new avenue to early diagnostics and drug screening with high sensitivity.

300 device and cell-free protein expression for drug screening, with advantages in less reagent consumpt